Rx News For Physicians Archive

2008

Regence’s coverage policy developed to encourage generic alendronate (Fosamax®) is an excellent opportunity to reduce patients’ copayments
August 14, 2008

Important Information about Generic OxyContin®
June 13, 2008

MDeNews™ June 2008
Avastin® Approved for use in Metastatic Breast Cancer – The Controversial FDA Decision
June 2008

NHLBI Guidelines and clinical studies suggest that Advair® and Symbicort® should be reserved for patients not adequately controlled on ICS products
May 30, 2008

Actavis Totowa LLC announced the voluntary recall of Digitek® (digoxin) for all tablets under both the “Bertek” and “UDL” label
May 7, 2008

MDeNews™ January 2008
Erythropoetin Stimulating Agents and Chemotherapy Induced Anemia - Emerging Safety Concerns
January 2008

MDeNews™  June 2008
Avastin® Approved for use in Metastatic Breast Cancer – The Controversial FDA Decision

MDeNews™  January 2008
Erythropoetin Stimulating Agents and Chemotherapy Induced Anemia – Emerging Safety Concerns

2007

The Delfini Group™, LLC, are leaders in evidence and value-based solutions in health care.
Regarding RegenceRx they have stated that they “know of no group today…that is doing a finer job applying evidence-based medicine principles.” Read about The Delfini Group and the RegenceRx process.

FDA Alert – New Avandia Warning Information Reflects Possible Heart Attack Risk
The FDA informed healthcare professionals of new information about potential increased risk for heart attacks added to the existing boxed warning in Avandia's prescribing information.
November 20, 2007

MDeNews™ August 2007
Avandia^® and Cardiovascular Risk – Implications for Patients and Providers
August 29, 2007

FDA Alert – FDA Permits Restricted Zelnorm Use
The FDA announced it’s permitting restricted use of Zelnorm under investigational new drug treatment protocol.
July 30, 2007

MDeNews™  June 2007
Brand v. Generic Antidepressants for the Treatment of Depression: What Does the Evidence Really Say?
June 27, 2007

Safety Information - Ortho Evra© and desogestrel-containing Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives concluded.
March 30, 2007

MDeNews™ March 2007
The ADOPT Study: Implications for the Choice of Initial Oral Hypoglycemic Therapy

Safety Information - Ortho Evra© and desogestrel-containing Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives concluded.
March 30, 2007

Generics First – Statin Program
In just the last year, high-quality statin generics that are able to provide up to 40% LDL-C lowering have become available. 
February 2, 2007

MDeNews™ January 2007
In response to requests for clinical updates, generic medication release dates and special member program changes we’ve developed MDeNews™.  To receive this quarterly electronic newsletter send an email to MDeNews@regence.com.  Please include the provider’s: (1) name; (2) email address; and (3) contact phone number.  Providers may also request the newsletter by calling 1 (877) 356-7763 and leaving the above information.
January 11, 2007